drugset / Trial / NCT00539760
A Phase I Rheumatoid Arthritis Study in Healthy Volunteers
RandomizedParallel-groupSingle-blindTreatment
Summary
GSK182771 is a domain antibody targeting the interleukin (IL)-1 receptor which is being developed for the treatment of rheumatoid arthritis. This study is being done in healthy volunteers to verify the safety and tolerability of GSK182771
Timeline
- Start
- 2007-09-05
- Primary completion
- 2008-04-05
- Completion
- 2008-04-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GSK1827771 | Unknown | 0.3 mg | Subcutaneous |